EQS-Adhoc: BB Biotech AG publishes its interim report

Ad hoc announcement pursuant to Art. 53 LR

April 25, 2025

BB Biotech AG publishes its interim report

BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2025, which covers the results of its business activities for the first three months of 2025.

Based on the consolidated accounts of BB Biotech AG, net loss for the period ended March 31, 2025, amounted to CHF 241 mn (profit of CHF 260 mn in the same period 2024). For an investment company, the results reflect the share price development of the companies held in the portfolio.

The interim report as at March 31, 2025, is available under report.bbbiotech.ch/Q125 or www.bbbiotech.com.

For further information:
Bellevue Asset Management AG
Theaterstrasse 12, 8001 Zurich, Switzerland, tel. +41 44 267 67 00

Head Investment Management Team BB Biotech
Dr. Christian Koch

Investor Relations
ir@bbbiotech.com
Claude Mikkelsen, cmi@bellevue.ch

Media Relations
Tanja Chicherio, tch@bellevue.ch

www.bbbiotech.com

 
Company profile 
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.